Praxis Precision Medicines, Inc. (PRAX)
Health Care ยท Pharmaceutical Preparations
Praxis Precision Medicines, Inc. (PRAX) is listed on Nasdaq, where its shares have traded since October 16, 2020. SentiSense covers Praxis Precision Medicines, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Marcio Souza is its chief executive officer. The company reports 10,998 employees, and its corporate website is www.praxismedicines.com.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Latest reported results
Praxis Precision Medicine Inc reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 301 institutions reported holding PRAX, with 33.7 million shares worth $11.3 billion in aggregate. The largest reported holders were Janus Henderson (Jupiter Topco), Vanguard and FMR.
More on PRAX
- PRAX sentiment: whether news and social coverage of Praxis Precision Medicines, Inc. leans bullish or bearish, and the stories driving it.
- PRAX ownership: all 301 reporting institutions, plus insider and congressional trades.
- PRAX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Praxis Precision Medicines, Inc. do?
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance.
What sector is PRAX in?
SentiSense classifies Praxis Precision Medicines, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does PRAX stock trade?
Praxis Precision Medicines, Inc. (PRAX) is listed on Nasdaq, where its shares have traded since October 16, 2020.
Who is the CEO of Praxis Precision Medicines, Inc.?
Marcio Souza is the chief executive officer of Praxis Precision Medicines, Inc..